Inno-Gene SA
WSE:IGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Inno-Gene SA
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | PL |
| Market Cap | 17.7m PLN |
| Gross Margin |
-44%
|
| Country | US |
| Market Cap | 1.3T USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 196.3B USD |
| Gross Margin |
41%
|
| Country | US |
| Market Cap | 170.3B USD |
| Gross Margin |
60%
|
| Country | KR |
| Market Cap | 66.5T KRW |
| Gross Margin |
50%
|
| Country | CH |
| Market Cap | 37.6B CHF |
| Gross Margin |
29%
|
| Country | US |
| Market Cap | 38.5B USD |
| Gross Margin |
55%
|
| Country | US |
| Market Cap | 36.7B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 26.4B USD |
| Gross Margin |
59%
|
| Country | US |
| Market Cap | 23B USD |
| Gross Margin |
35%
|
| Country | US |
| Market Cap | 22.3B USD |
| Gross Margin |
64%
|
Inno-Gene SA
Glance View
Inno Gene SA engages in the management of startup biotechnology companies. The company is headquartered in Poznan, Woj. Wielkopolskie. The company went IPO on 2011-02-08. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Inno-Gene SA's most recent financial statements, the company has Gross Margin of -44.2%.
You don't have any saved screeners yet
